Type 1 Diabetes Mellitus Provoked by Peginterferon α-2b Plus Ribavirin Treatment for Chronic Hepatitis C

Junichirou Tanaka; Kazushi Sugimoto; Katsuya Shiraki; Tetsuya Beppu; Kentarou Yoneda; Hiroyuki Fuke; Norihiko Yamamoto; Keiichi Ito; Yoshiyuki Takei

doi:10.2169/internalmedicine.47.0653

CASE REPORTS

Type 1 Diabetes Mellitus Provoked by Peginterferon α-2b Plus Ribavirin Treatment for Chronic Hepatitis C

Junichirou Tanaka, Kazushi Sugimoto, Katsuya Shiraki, Tetsuya Beppu, Kentarou Yoneda, Hiroyuki Fuke, Norihiko Yamamoto, Keiichi Ito, Yoshiyuki Takei

Author information

Junichirou Tanaka
Department of Gastroenterology, Mie University School of Medicine
Kazushi Sugimoto
Department of Gastroenterology, Mie University School of Medicine
Katsuya Shiraki
Department of Gastroenterology, Mie University School of Medicine
Tetsuya Beppu
Department of Gastroenterology, Mie University School of Medicine
Kentarou Yoneda
Department of Gastroenterology, Mie University School of Medicine
Hiroyuki Fuke
Department of Gastroenterology, Mie University School of Medicine
Norihiko Yamamoto
Department of Gastroenterology, Mie University School of Medicine
Keiichi Ito
Department of Gastroenterology, Mie University School of Medicine
Yoshiyuki Takei
Department of Gastroenterology, Mie University School of Medicine

Keywords: type 1 diabetes mellitus, peginterferon α-2b, chronic hepatitis C

JOURNAL OPEN ACCESS

2008 Volume 47 Issue 8 Pages 747-749

DOI https://doi.org/10.2169/internalmedicine.47.0653

Details

Abstract

A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant α-2b peginterferon plus ribavirin for chronic hepatitis C. Pancreatic autoantibody tests were negative before the start of therapy, but a significant increase in glutamic acid decarboxylase (GAD) antibody titer was seen after 24 weeks of treatment. Six months after the onset of type 1 diabetes mellitus, the patient continues to receive 40 units of insulin daily. The clinical course suggested that recombinant α-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.

Corresponding author

Register with J-STAGE for free!